Hemispherx Biopharma (HEB) Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
9/12/2013 9:28:29 AM
PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced that at the Options for the Control of Influenza VIII Conference in Cape Town, South Africa held 5-10 September, 2013, that a scientific advisor to Hemispherx, Professor Dr. Juergen A. Richt, DVM, Ph.D., Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Regents Distinguished Professor at Kansas State University, and an Eminent Scholar of Kansas Bioscience Association (KBA), described his experiments in human lung cells evidencing that Alferon N Injection®, the only multi-species, natural interferon approved in the U.S. for the treatment of human refractory HPV genital warts, is biologically active, in low doses, against various classes of viruses occurring naturally in animals and humans.
Help employers find you! Check out all the jobs and post your resume.
comments powered by